Drug name - Sivextro
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8420676 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Feb, 2028
(5 years from now) | |
| US7816379 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Jun, 2028
(5 years from now) | |
| US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(7 years from now) | |
| US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(7 years from now) | |
| US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(8 years from now) | |
| CN102439006A | CUBIST PHARMS LLC | Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate |
Jun, 2017
(5 years ago) | |
| CN102702184A | CUBIST PHARMS LLC | Novel Oxazolidinone Derivatives |
Dec, 2021
(9 months ago) | |
| CN102516238A | CUBIST PHARMS LLC | Novel Derivatives Of Oxazolidinone |
Dec, 2021
(9 months ago) | |
| CN1894242A | CUBIST PHARMS LLC | New Oxazolidone Derivative |
Dec, 2021
(9 months ago) | |
| CN102702184B | CUBIST PHARMS LLC | Oxazolidinone Derivatives |
Dec, 2021
(9 months ago) | |
| CN1894242B | CUBIST PHARMS LLC | Novel Oxazolidinone Derivatives |
Dec, 2021
(9 months ago) | |
| CN102516238B | CUBIST PHARMS LLC | Oxazolidinone Derivatives |
Dec, 2021
(9 months ago) | |
| CN101982468A | CUBIST PHARMS LLC | An Oxazolidinone Derivative And Pharmaceutical Composition Comprising The Same |
Jan, 2022
(8 months ago) | |
| CN101982468B | CUBIST PHARMS LLC | Oxazolidinone Derivatives And Pharmaceutical Composition Containing The Derivative |
Jan, 2022
(8 months ago) | |
| IN200602167P4 | CUBIST PHARMS LLC | Oxazolidinone Derivatives |
Dec, 2024
(2 years from now) | |
| IN236862B | CUBIST PHARMS LLC | Novel Oxazolidinone Derivatives |
Dec, 2024
(2 years from now) | |
| EP2305657B1 | CUBIST PHARMS LLC | Oxazolidinone Derivatives |
Dec, 2024
(2 years from now) | |
| EP2305657A3 | CUBIST PHARMS LLC | Oxazolidinone Derivatives |
Dec, 2024
(2 years from now) | |
| EP2305657A2 | CUBIST PHARMS LLC | Oxazolidinone Derivatives |
Dec, 2024
(2 years from now) | |
| EP1699784B1 | CUBIST PHARMS LLC | Novel Oxazolidinone Derivatives |
Dec, 2029
(7 years from now) | |
| EP1699784A4 | CUBIST PHARMS LLC | Novel Oxazolidinone Derivatives |
Dec, 2029
(7 years from now) | |
| EP1699784A1 | CUBIST PHARMS LLC | Novel Oxazolidinone Derivatives |
Dec, 2029
(7 years from now) | |
| EP2393808B1 | CUBIST PHARMS LLC | Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate |
Feb, 2030
(7 years from now) | |
| EP2393808A1 | CUBIST PHARMS LLC | Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate |
Feb, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(7 years from now) | |
| US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(7 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.